DNLI
Price
$15.96
Change
+$0.76 (+5.00%)
Updated
Oct 15, 11:16 AM (EDT)
Capitalization
2.22B
15 days until earnings call
Intraday Buy/Sell Signals
MIRM
Price
$73.28
Change
+$1.11 (+1.54%)
Updated
Oct 14 closing price
Capitalization
3.68B
28 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

DNLI vs MIRM

Header iconDNLI vs MIRM Comparison
Open Charts DNLI vs MIRMBanner chart's image
Denali Therapeutics
Price$15.96
Change+$0.76 (+5.00%)
Volume$1.7K
Capitalization2.22B
Mirum Pharmaceuticals
Price$73.28
Change+$1.11 (+1.54%)
Volume$376.82K
Capitalization3.68B
DNLI vs MIRM Comparison Chart in %
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MIRM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. MIRM commentary
Oct 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Hold and MIRM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 15, 2025
Stock price -- (DNLI: $15.21 vs. MIRM: $73.28)
Brand notoriety: DNLI and MIRM are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 133% vs. MIRM: 49%
Market capitalization -- DNLI: $2.22B vs. MIRM: $3.68B
DNLI [@Biotechnology] is valued at $2.22B. MIRM’s [@Biotechnology] market capitalization is $3.68B. The market cap for tickers in the [@Biotechnology] industry ranges from $105.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.07B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileMIRM’s FA Score has 1 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • MIRM’s FA Score: 1 green, 4 red.
According to our system of comparison, MIRM is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 7 TA indicator(s) are bullish while MIRM’s TA Score has 3 bullish TA indicator(s).

  • DNLI’s TA Score: 7 bullish, 3 bearish.
  • MIRM’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than MIRM.

Price Growth

DNLI (@Biotechnology) experienced а +2.08% price change this week, while MIRM (@Biotechnology) price change was -0.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.76%. For the same industry, the average monthly price growth was +13.99%, and the average quarterly price growth was +268.92%.

Reported Earning Dates

DNLI is expected to report earnings on Oct 30, 2025.

MIRM is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (+0.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MIRM($3.68B) has a higher market cap than DNLI($2.22B). MIRM YTD gains are higher at: 77.219 vs. DNLI (-25.368). MIRM has higher annual earnings (EBITDA): -18.79M vs. DNLI (-521.52M). DNLI has more cash in the bank: 899M vs. MIRM (305M). DNLI has less debt than MIRM: DNLI (46.6M) vs MIRM (319M). MIRM has higher revenues than DNLI: MIRM (429M) vs DNLI (0).
DNLIMIRMDNLI / MIRM
Capitalization2.22B3.68B60%
EBITDA-521.52M-18.79M2,775%
Gain YTD-25.36877.219-33%
P/E RatioN/AN/A-
Revenue0429M-
Total Cash899M305M295%
Total Debt46.6M319M15%
FUNDAMENTALS RATINGS
DNLI vs MIRM: Fundamental Ratings
DNLI
MIRM
OUTLOOK RATING
1..100
1453
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
58
Fair valued
PROFIT vs RISK RATING
1..100
1007
SMR RATING
1..100
9796
PRICE GROWTH RATING
1..100
6139
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MIRM's Valuation (58) in the null industry is somewhat better than the same rating for DNLI (93) in the Biotechnology industry. This means that MIRM’s stock grew somewhat faster than DNLI’s over the last 12 months.

MIRM's Profit vs Risk Rating (7) in the null industry is significantly better than the same rating for DNLI (100) in the Biotechnology industry. This means that MIRM’s stock grew significantly faster than DNLI’s over the last 12 months.

MIRM's SMR Rating (96) in the null industry is in the same range as DNLI (97) in the Biotechnology industry. This means that MIRM’s stock grew similarly to DNLI’s over the last 12 months.

MIRM's Price Growth Rating (39) in the null industry is in the same range as DNLI (61) in the Biotechnology industry. This means that MIRM’s stock grew similarly to DNLI’s over the last 12 months.

MIRM's P/E Growth Rating (100) in the null industry is in the same range as DNLI (100) in the Biotechnology industry. This means that MIRM’s stock grew similarly to DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIMIRM
RSI
ODDS (%)
Bullish Trend 8 days ago
87%
Bearish Trend 8 days ago
79%
Stochastic
ODDS (%)
Bearish Trend 8 days ago
86%
Bullish Trend 8 days ago
82%
Momentum
ODDS (%)
Bullish Trend 8 days ago
72%
Bearish Trend 8 days ago
71%
MACD
ODDS (%)
Bullish Trend 8 days ago
78%
Bearish Trend 8 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 8 days ago
77%
Bearish Trend 8 days ago
67%
TrendMonth
ODDS (%)
Bullish Trend 8 days ago
73%
Bearish Trend 8 days ago
69%
Advances
ODDS (%)
Bullish Trend 13 days ago
76%
Bullish Trend 16 days ago
77%
Declines
ODDS (%)
Bearish Trend 9 days ago
82%
Bearish Trend 14 days ago
66%
BollingerBands
ODDS (%)
Bullish Trend 8 days ago
84%
Bullish Trend 8 days ago
77%
Aroon
ODDS (%)
Bearish Trend 8 days ago
83%
Bearish Trend 8 days ago
57%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MIRM
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
VGSLX127.001.31
+1.04%
Vanguard Real Estate Index Admiral
GRGTX49.620.44
+0.89%
Goldman Sachs Equity Income Inv
EPLCX23.410.19
+0.82%
NYLI Epoch U.S. Equity Yield Class I
MMELX16.440.12
+0.74%
MassMutual Mid Cap Growth Adm
EAERX23.12-0.07
-0.30%
Eaton Vance Stock A

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with NRIX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+1.54%
NRIX - DNLI
58%
Loosely correlated
-5.56%
RGNX - DNLI
54%
Loosely correlated
-0.79%
BEAM - DNLI
54%
Loosely correlated
+0.12%
IMVT - DNLI
54%
Loosely correlated
+0.81%
OCUL - DNLI
54%
Loosely correlated
-5.23%
More

MIRM and

Correlation & Price change

A.I.dvisor indicates that over the last year, MIRM has been loosely correlated with XERS. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if MIRM jumps, then XERS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MIRM
1D Price
Change %
MIRM100%
+1.54%
XERS - MIRM
51%
Loosely correlated
+2.14%
IRON - MIRM
44%
Loosely correlated
+1.45%
NRIX - MIRM
43%
Loosely correlated
-5.56%
DNLI - MIRM
42%
Loosely correlated
+1.54%
RNA - MIRM
40%
Loosely correlated
-1.70%
More